Genflow Biosciences Share Discussion Threads

[kubera369] 22/1/2024 15:58

There has been a broker update today on Genflow Does any one have access to what was mentioned?Looks like the Bio sector is certainly hotting up and Genflow are at the forefront and primed to do extremely well Still waiting for the investors update from Eric and should add a lot more value and a higher share price I'm confident that institutional interest will gather now if it has not already Truly excited to be invested here

[pie chart] 22/1/2024 15:48

Below are some exciting updates which have taken place within the Biotech/Pharma industry over the last week. 💊

🍾 - Tr1X have successfully raised $75 Million to develop treatments targeting immune cells for autoimmune conditions.✅
🍾 - Comanche Biopharma have raised $75 Million to advance its mission to develop and make globally available the first treatment targeting a root cause of preeclampsia.✅
🍾 - A new biotech venture capital firm Mirae Asset Capital Life Science emerged last Thursday with $50 Million to back as many as eight private life sciences start-up companies.✅
🍾 - BridgeBio has successfully raised up to $1.25 Billion as it prepares to commercialize & continue running multiple clinical trials across cardiorenal, oncology and other disease areas.✅
🍾 - Alto Neuroscience has announced that it has filed for a proposed initial public offering (IPO) to raise up to $100 Million.✅
🍾 - GenFlow Biosciences has announced new collaborations with Revatis & EXO Biologics on two new research programs, backed by non-dilutive financial backing from the Government of Wallonia in Belgium.✅
🍾 - GSK has announced that it has completed the sale of 300 million shares in Haleon the consumer health giant, netting $1.23 Billion in the process.✅
🍾 - DISCO Pharmaceuticals GmbH has emerged from stealth mode with $21.8 Million financing to bring its cancer cell surface mapping technology-developed candidates to oncology therapeutics.✅

[bri15] 22/1/2024 11:58

Forgot to add that this only has a £6 Million market cap and the sector we are in could be worth £ Billions, brilliant, just brilliant 👏

[bri15] 22/1/2024 11:55

I have been loading up here today,this company is going to be massive, funding in place for over a year, brilliant team, brilliant, just brilliant 👏

[moneymunch] 22/1/2024 10:19

Perfectly poised and primed!!! Gla :-)

[kubera369] 22/1/2024 09:20

Investors update should be announced any time this week and can be intraday Hold on :)

[moneymunch] 22/1/2024 07:19

Swiss longevity biotech startup Timeline bags €60.6M from L’Oréal, Nestlé, others

January 18, 2024

“Longevity is a new definition of beauty, at the intersection of different scientific disciplines, from decoding biological markers to analysing external exposure. Our investment in Timeline is exciting for its potential to transpose key hallmarks of longevity onto skin health and beauty.”

[kubera369] 21/1/2024 11:47

Genflow is currently developing a pipeline of SIRT6 gene therapies, with three programs targeting Werner Syndrome, an aggressive form of non-alcoholic fatty liver disease (NASH), and pet longevity. The company's lead compound is a suspension of an adeno-associated viral vector-based gene therapy based on a variant of the human SIRT6 gene, which is associated with longevity in centenarians.Genflow will be bought out before commercialisation imo

[moneymunch] 21/1/2024 11:28

Genflow in the mix. Gla ;-)


September 2023

Pfizer-backed VitaDAO spins out biotech company

VitaDAO, which funds longevity research, announced the $300,000 financing of a biotechnology company, the DAO's first such investment



............

Vitadao

VDP-117 Magnaetus Therapeutics
Proposals
Active Proposals

.......................

Reviewer 2

Although no direct relationship or direct mechanistic action with aging, I am enthusiastic about their idea to use parts of the ECM and the protein of interest to target obesity (and metabolic dysregulation), which definitely will have a big impact on the aging society. Also, if they succeed, Novo Nordisk or Eli Lilly is likely to acquire them.

Reviewer 3

After reevaluating the data based on the company’s answers, they do indeed look promising and would allow VitaDAO to enter the weight-loss market. From a commercial perspective, my key concerns are the limited knowledge by the team of what is being developed outside of the two weight-loss drugs that are already commercialized and the lack of a Target Product Profile to be presented to physicians for feedback. I would also recommend as soon as it is feasible to generate head-to-head data vs semaglutide (Novo Nordisk) and tirzepatide (Eli Lilly). Also, given the size of the market, this is not a drug that can be developed and sold on its own, and Business Development activities targeted at Big Pharma must be initiated as soon as possible






Global online DAO approves launch and financing of MatrixBio to optimal drug candidates for age-related diseases.

VitaDAO, the global online community driving early-stage longevity research through innovative funding collaborations has announced the launch of its very first biotech company – Matrix Biosciences. This significant milestone comes from a community-wide vote and approval in favor of a collaboration with Vera Gorbunova, PhD, Co-Chair of the University of Rochester’s Aging Research Center.

[kubera369] 21/1/2024 11:27

What If institutional interest lands here with U.S interest ?With this latest news and the forthcoming news, I am now confident that the shares will be in big demand and will also be held tightly by those who are waiting for the inevitable Genflow has started up this year with a very positive stride and will continue to do so as more news pours in and investor demand/appetite increases With no share dilution and a small free float = expect fireworks and let the small time sellers take their profits as we head on higher throughout the year.Longevity, SIRT6, Anti ageing is the new blockchain and A I for this year and beyond. We are in the hottest sector and it's all warming up.Loads of potential surprises to catapult the SP

[luckyabbeygale] 21/1/2024 10:55

The bigger seller is no different to having Lanstead.
Not always a bad thing, since by the time the dilution has gone. You end up owning around 3 times as many shares.
This is what happened to me with my main share in Oriole and ended up going up from 0.08p to 0.35p.

[moneymunch] 21/1/2024 09:52

Another potential imminent non-dilutive award for Genflow, who were awarded a $50k prize in September 2023 along with a new collaboration with Magnaetus Therapeutics from the healthspan challenge and now go forward to the next stage of the challenge, where $1 million will be awarded in January 2024 for the most promising longevity therapies, followed by a grand prize of $5m in June. Gla ;-)


September 2023

Developing therapeutic agents reverse ageing and metabolic decline

Cary Depel; Paul Baldock; Guy Barry |

Magnaetus Therapeutics; Eric Leire, MD | Genflow Biosciences

Competition Sponsor: US National Academy of Medicine

Awardee Year: 2023



Magnaetus Therapeutics believes that in order for longevity measures to be most effective, lifespan increases must be twinned with supportive metabolic interventions. This will ensure the ultimate aim of greater quality, as well as quantity of life, for the increasing majority of our population that is overweight/obese.

To deliver on this aim, Magnaetus is working with Genflow Biosciences to develop peptide therapeutics based upon the multiple metabolic activities of a novel circulating protein. Serum levels of this hormone are increased by exercise and calorie restriction, and suppressed by ageing, obesity and inactivity. It exhibits endocrine effects across numerous aspects of the energy economy, acting to mimic the downstream benefits of exercise and calorie restriction.

Longevity is directly targeted through a feed-forward loop with mTOR suppression. This is coupled with additional capabilities, including appetite suppression, fat burning and insulin production/sensitivity. The discrimination of these activities is realised through selection of individual loops of the parent protein’s repeated helical structure, enabling tailoring of therapeutic response to patient needs through production of specific peptide therapeutics.

[moneymunch] 21/1/2024 09:09

Mrs Bauer's orderley disposal of her husbands 14.5m shares, announced in March 2023, is no doubt done, and no doubt led to the slide in share price to January's all time low of c1.4p during the year as impatient pi's offloaded as the share price continued its slide. Any recent sellers are probably those who are banking their profits, 20% up pre-funding news from 1.4p to c1.65p and 30% up on the latest news at 2p plus, all in the mix regardless and Genflow are now set for a very exciting year according to Eric and the team, with the expectation of lots of positive newsflow to drive the share price North in the coming days and weeks....full market interest and investor focus is turning this way and so every chance Genflow will be one of the star shares of 2024.....Right time, right place!!! Gla holders....On and most definetly UP!!! ( imho ) ;-)

[marmiesz] 20/1/2024 18:35

Agee with this though I'm not sure how much of an impact it will have. We seem to have a persistent seller who has been selling for most of the year. Until we are rid of them, any uplift in share price will be limited. The sooner they go the better. We should be trading in the 8-12p range, imo.Marmie

[kubera369] 20/1/2024 13:40

Expecting the year end share holder letter to come in next week as per Eric's New Year posting on linked inI see more rises next week as the share letter will add a lot more value and updates to what has already been mentioned this week Loads of newsflow should be updated then and the share price should gain new levels Good luck

[moneymunch] 20/1/2024 08:29

Longevity biotech collaborates with Revatis and EXO Biologics on new research into sarcopenia and SIRT6 MRNA delivery.

Longevity biotech Genflow Biosciences has teamed up with Revatis and EXO Biologics on two new longevity research programs, fueled by grants from the Government of Wallonia in Belgium. Genflow is developing gene therapies that target the aging process, with a focus on reducing and delaying age-related diseases.

One of the new research programs, conducted in collaboration with cell therapy company Revatis, is focused on addressing the issue of age-related muscle loss. With funding of €1.34 million, the three-year initiative aims to provide insights into the mechanisms of sarcopenia – the muscle deterioration associated with aging.

Simultaneously, Genflow and exosome-focused biotech EXO Biologics are embarking on a three-year scientific program focusing on mRNA delivery. Supported by a grant of €1.55 million, the initiative will explore an approach using exosomes to encapsulate and transport Genflow’s SIRT6 gene therapy. The ultimate goal is to enable the development of therapeutic interventions for Werner Syndrome, an accelerated aging condition, and other age-related conditions.

Dr Eric Leire, CEO of Genflow said that the new research programs will allow the company to make “meaningful advancements” in the field of longevity.

“Launching both of these programs represents a strategic move to enhance our research capabilities, while contributing to the understanding of age-related conditions,” he said.

Genflow is currently developing a pipeline of SIRT6 gene therapies, with three programs targeting Werner Syndrome, an aggressive form of non-alcoholic fatty liver disease (NASH), and pet longevity. The company’s lead compound is a suspension of an adeno-associated viral vector-based gene therapy based on a variant of the human SIRT6 gene, which is associated with longevity in centenarians.

Disclosure: First Longevity Ltd which operates this website (Longevity.Technology) has a commercial interest in Genflow Biosciences Ltd.

[kubera369] 19/1/2024 18:14

Mr and Mrs Bauer ?

[steg] 19/1/2024 16:53

I have been puzzled for a while by who has been selling for months now because for sure the selling brought us back from 5p to 1.5p and clearly is still going on, I won’t say because I don’t know 100% but I think it’s from 2 sources who did own a large % of Genf combined and are linked. Anyway whoever it is hopefully they will finish soon and we can get going in the right direction

[kubera369] 19/1/2024 15:42

News is incoming any day now as per Eric's announcement on the Genflow linked in account.I would only be buying

[gah123] 19/1/2024 14:39

Thanks holding for 5p+, will top up if it dips.

[pie chart] 19/1/2024 12:24

No you are in a good place. This is yet to be truly discovered and still under the radar.

[gah123] 19/1/2024 11:55

Or am I missing something

[gah123] 19/1/2024 11:52

Invested yesterday at 2p what a gem, can't believe it's so cheap. Anything under 20m mcap is a steal surely.

[moneymunch] 19/1/2024 07:39

Ditto, a PlusOne Coin Top Post, and don't forget potential news on Genflow's GF-4001 Non-Human Pipeline Anti-aging for veterinary use (dogs), highlighted and perhaps significant by Revatis's veterinary R & D. Gla ;-)

[northeast14] 19/1/2024 07:18

Steg- fantastic post! A great balanced deep dive into Genf there.
GL